The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 08, 2010
Filed:
Aug. 20, 2007
David M. Stern, Great Neck, NY (US);
Ann Marie Schmidt, Franklin Lakes, NJ (US);
Steven Marso, Shawnee, KS (US);
Eric Topol, Chagrin Falls, OH (US);
A. Michael Lincoff, Orange Village, OH (US);
David M. Stern, Great Neck, NY (US);
Ann Marie Schmidt, Franklin Lakes, NJ (US);
Steven Marso, Shawnee, KS (US);
Eric Topol, Chagrin Falls, OH (US);
A. Michael Lincoff, Orange Village, OH (US);
The Trustees of Columbia University in the City of New York, New York, NY (US);
The Cleveland Clinic Foundation, Cleveland, OH (US);
Abstract
This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels. The invention also provides a method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to prevent exaggerated restenosis in the subject.